These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://safiyadxyh864932.post-blogs.com/59781623/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide